Research
Hormonal
Both tirzepatide and semaglutide significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels in solid-organ transplant recipients.
Both medications can be considered effective options for managing diabetes in transplant patients.
StrongSupportsmedium confidence
Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
Why this rating
The study is a retrospective chart review involving a specific patient cohort.
Source
Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients.
Omar El Khatib et al. · Experimental and Clinical Transplantation · 2026
cohort · n=73
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →